Open trial to evaluate if proton pump inhibitor pantoprazole (PPI) in combination with L. reuteri DSM 17938 may eradicate H. pylori infection in adults. Intervention was administered for 8 weeks + follow-up at 4-6 weeks thereafter. Twenty-two (22) subjects were included, given L. reuteri at the dose of 1×10^8 CFU/d plus 20 mg x 2 of pantoprazole/d.

L. reuteri plus PPI twice a day cured 13.6 % (3/22) of patients with H. pylori infection by intention-to-treat analysis and 14.2 % (3/21) by per protocol analysis. There was a significant reduction in urease activity, comparing baseline to 4–6 weeks post therapy.

Conclusion: L. reuteri may have a potential role in H. pylori eradication therapy if the cure rate can be improved by changes in dose, dosing interval, or duration of therapy.

 

Reference

Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014;9:649-654.

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.